These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16049961)

  • 1. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
    Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
    Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
    Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
    Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.
    Pérez-Tenorio G; Stål O;
    Br J Cancer; 2002 Feb; 86(4):540-5. PubMed ID: 11870534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE; Fanelli MA; Ciocca DR
    J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
    Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
    Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
    Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
    J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERβ and HER-2 expression.
    Wang X; Yi L; Zhu Y; Zou J; Hong Y; Zheng W
    Tumori; 2011; 97(2):185-90. PubMed ID: 21617713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Grell P; Fabian P; Khoylou M; Radova L; Slaby O; Hrstka R; Vyzula R; Hajduch M; Svoboda M
    Int J Oncol; 2012 Oct; 41(4):1204-12. PubMed ID: 22842582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
    Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hashizume K; Ono M; Kouno T; Ando M; Tamura K; Katsumata N; Hasegawa T; Kinoshita T; Fujiwara Y
    Med Oncol; 2009; 26(3):344-9. PubMed ID: 19016009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
    Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan LX; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi GN; Michiels S; Delaloge S; Esteva FJ
    Ann Oncol; 2008 Feb; 19(2):315-20. PubMed ID: 17804473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
    D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
    Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
    Schmitz KJ; Grabellus F; Callies R; Otterbach F; Wohlschlaeger J; Levkau B; Kimmig R; Schmid KW; Baba HA
    Breast Cancer Res; 2005; 7(2):R194-203. PubMed ID: 15743500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A; McGregor SR
    Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt kinases in breast cancer and the results of adjuvant therapy.
    Stål O; Pérez-Tenorio G; Akerberg L; Olsson B; Nordenskjöld B; Skoog L; Rutqvist LE
    Breast Cancer Res; 2003; 5(2):R37-44. PubMed ID: 12631397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.